Magnetic seizures: a new hope for schizophrenia without the memory fog?
NCT ID NCT06672588
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares Magnetic Seizure Therapy (MST) to standard Electroconvulsive Therapy (ECT) in 80 people with treatment-resistant schizophrenia or schizoaffective disorder. MST uses magnetic pulses to trigger a controlled seizure, aiming to ease symptoms like hallucinations and depression while causing fewer memory problems than ECT. Researchers will track symptom changes, thinking skills, and side effects over the treatment course.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Magnetic Seizure Therapy (MST) device
- What this could lead to
- If MST works, it could offer a safer, more tolerable alternative to ECT for people with hard-to-treat schizophrenia, reducing symptoms and cognitive side effects.
- What could go wrong
- This is an early-stage trial with only 80 participants, so results may not apply to everyone. MST may not be as effective as ECT, and risks like seizures or memory issues remain possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Nov 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. are inpatients or outpatients; 2. demonstrate capacity to consent according to the MacArthur competence assessment tool for clinical research (MacCAT-CR); 3. have a DSM-5 diagnosis of Schizophrenia or Schizoaffective Disorder for at least 2 years, as determined by the MINI International Neuropsychiatric Interview - Version 7 (MINI-7.0); 4. are 18 years of age or older; 5. have demonstrated resistance to at least 2 antipsychotics of 600 mg of chlorpromazine equivalents for at least 6 weeks; 6. have a BPRS score at baseline of at least moderate severity (\>4) on one of the four psychotic items (i.e., hallucinatory behavior, suspiciousness, conceptual disorganization, unusual thought content) or at least 12 on these 4 items combined; 7. are considered to be appropriate to receive convulsive therapy as assessed by an ECT attending psychiatrist and a consultant anaesthesiologist; 8. are on an antipsychotic at an adequate dose and are agreeable to keeping their current antipsychotic treatment constant during the acute phase of the intervention; 9. are able to adhere to the intervention schedule; 10. meet the MST safety criteria; 11. If a woman of child-bearing potential: is willing to provide a negative pregnancy test and agrees not to become pregnant during trial participation. Exclusion Criteria: 1. have a history of MINI diagnosis of a substance use disorder (other than nicotine and caffeine) within the past three months; 2. have a concomitant major unstable medical illness; 3. are pregnant or intend to get pregnant during the study; 4. have probable dementia based on study investigator assessment; 5. have any significant neurological disorder or condition likely to be associated with increased intracranial pressure or a space occupying brain lesion, e.g., cerebral aneurysm; 6. present with a serious medical condition, 7. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed; 8. require a benzodiazepine with a dose \> lorazepam 2 mg/day or equivalent or any anticonvulsant due to the potential of these medications to limit the efficacy of both MST and ECT; 9. are unable to communicate in English fluently enough to complete the neuropsychological tests; 10. have a non-correctable clinically significant sensory impairment (i.e., cannot hear or see well enough to complete the neuropsychological tests).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre for Addiction and Mental Health
RECRUITINGToronto, Ontario, M6J 1H4, Canada
-
University of British Columbia Hospital
RECRUITINGVancouver, British Columbia, V6T 2A1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may reveal if You're taking your psychiatric medication
- Zapping the brain at the moment voices start
- Scientists probe brain's reward system in mental illness
- Desert plant tested against Clozapine's weighty side effects
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms